Retinal vein occlusion – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Retinal vein occlusion – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the safety and effectiveness of ANXV in patients with diabetic retinopathy or retinal vein occlusion https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-anxv-in-patients-with-diabetic-retinopathy-or-retinal-vein-occlusion/ Wed, 29 Apr 2026 15:09:49 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-anxv-in-patients-with-diabetic-retinopathy-or-retinal-vein-occlusion/ This study focuses on two eye conditions: Diabetic Retinopathy, which is damage to the retina caused by diabetes, and Retinal Vein Occlusion, a condition where a blood vessel in the eye becomes blocked. The purpose of the study is to evaluate the safety and tolerability of a treatment called ANXV, which is a recombinant human Annexin A5 protein. This medication will be given through an intravenous infusion, meaning it is delivered directly into a vein.

During the study, participants will receive the medication and will be monitored for any side effects or how their bodies react to the treatment. The process involves checking for anti-drug antibodies, which are substances the body might create to fight against a medication. Researchers will also look at various aspects of eye health and how the medication moves through the body.

]]> Study on the Effect of Aflibercept Injections in Patients with Central Retinal Vein Occlusion (CRVO) and Spontaneous Retinal Arterial Pulsations (SRAPs) https://clinicaltrials.eu/trial/study-on-the-effect-of-aflibercept-injections-in-patients-with-central-retinal-vein-occlusion-crvo-and-spontaneous-retinal-arterial-pulsations-sraps/ Wed, 29 Apr 2026 14:57:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-aflibercept-injections-in-patients-with-central-retinal-vein-occlusion-crvo-and-spontaneous-retinal-arterial-pulsations-sraps/ This clinical trial focuses on a condition called central retinal vein occlusion (CRVO), which affects the blood flow in the eye and can lead to vision problems. The study is investigating the use of a treatment called aflibercept, which is administered as an injection into the eye. Aflibercept is also known by other names, such as BAY 86-5321 and VEGF TRAP. The purpose of the study is to understand how the presence of spontaneous retinal arterial pulsations (SRAPs) can predict the outcome of CRVO in patients who receive aflibercept injections compared to those who do not.

Participants in the study will be monitored over a period of one year. During this time, their vision will be assessed to see how it changes from the beginning of the study to the end. The study will also track the number of aflibercept injections each participant receives and any changes in the thickness of the macula, which is a part of the eye that can swell in CRVO. This swelling is known as macular edema and will be evaluated by an eye specialist using a special imaging technique called OCT, which stands for optical coherence tomography.

The study aims to gather information on how effective aflibercept is in improving vision and managing symptoms in patients with CRVO. By comparing patients with and without SRAPs, researchers hope to better understand the role these pulsations play in the progression of the disease and the effectiveness of the treatment. This information could help improve treatment strategies for people with CRVO in the future.

]]> Study on Ranibizumab Injections and Laser Treatment for Macular Edema in Central Retinal Vein Occlusion Patients https://clinicaltrials.eu/trial/study-on-ranibizumab-injections-and-laser-treatment-for-macular-edema-in-central-retinal-vein-occlusion-patients/ Wed, 29 Apr 2026 14:26:22 +0000 https://clinicaltrials.eu/trial/study-on-ranibizumab-injections-and-laser-treatment-for-macular-edema-in-central-retinal-vein-occlusion-patients/ This clinical trial is focused on studying the treatment of macular edema caused by central retinal vein occlusion. Macular edema is a condition where fluid builds up in the macula, a part of the eye responsible for sharp vision, leading to vision problems. Central retinal vein occlusion occurs when the main vein in the retina becomes blocked, affecting blood flow and causing swelling. The treatment being studied involves the use of Ranibizumab, a medication that is injected into the eye to help reduce the swelling and improve vision. Ranibizumab is an anti-VEGF drug, which means it works by blocking a protein that can cause abnormal blood vessel growth and leakage in the eye.

The purpose of this study is to determine if the regular injections of Ranibizumab can be reduced or even stopped when combined with an early procedure called targeted peripheral laser photocoagulation. This procedure uses a laser to treat specific areas of the retina to help control the condition. Participants in the study will receive Ranibizumab injections, and some will also undergo the laser treatment. The study will monitor how long the injections are needed and whether the additional laser treatment can help reduce the need for them.

Throughout the study, participants will have regular check-ups to assess their vision and the thickness of the macula using a method called OCT (optical coherence tomography), which is a type of imaging test that provides detailed pictures of the retina. The study aims to find out if the combination of treatments can lead to a successful outcome, defined as a period of at least six months without needing further injections. The study will continue until 2026, allowing researchers to gather long-term data on the effectiveness of the treatment approach.

]]> Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases https://clinicaltrials.eu/trial/study-on-the-safety-and-use-of-avt06-aflibercept-for-patients-with-chorioretinal-vascular-diseases/ Wed, 29 Apr 2026 14:26:19 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-use-of-avt06-aflibercept-for-patients-with-chorioretinal-vascular-diseases/ This clinical trial is focused on studying the handling and safety of a treatment called Aflibercept, which is used for various eye conditions. These conditions include neovascular age-related macular degeneration (a type of vision loss in older adults), diabetic macular edema (swelling in the retina due to diabetes), myopic choroidal neovascularization (abnormal blood vessel growth in the eye due to severe nearsightedness), retinal vein occlusion (blockage of veins in the retina), and diabetic retinopathy (damage to the retina caused by diabetes). The treatment is administered as a solution for injection using a pre-filled syringe, referred to as AVT06.

The purpose of this study is to ensure that the AVT06 pre-filled syringe is handled correctly and safely, and to evaluate the safety of the treatment when injected into the eye. Participants in the study will receive the treatment through an injection into the eye, known as intravitreal use. The study will follow participants over a period to monitor the safety and effectiveness of the treatment. There is also an optional extension phase for further observation.

Throughout the study, the focus will be on the successful administration of the treatment and monitoring any side effects related to the eye. The study aims to provide valuable information on the safe use of Aflibercept in treating these eye conditions, helping to improve treatment options for patients with these diseases.

]]> Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-aflibercept-for-patients-with-vision-loss-due-to-macular-edema-from-retinal-vein-blockage/ Wed, 29 Apr 2026 14:23:28 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-aflibercept-for-patients-with-vision-loss-due-to-macular-edema-from-retinal-vein-blockage/ This clinical trial is focused on studying a condition called macular edema, which is a swelling in the central part of the retina, known as the macula. This swelling is caused by a blocked vein in the retina, a condition referred to as retinal vein occlusion. The study is investigating the effectiveness and safety of a medication called aflibercept, which is given as an injection into the eye. Aflibercept is a protein-based treatment that helps reduce swelling and improve vision.

The purpose of the study is to compare two different doses of aflibercept. One group of participants will receive 8 mg of aflibercept every 8 weeks, while another group will receive 2 mg every 4 weeks. The study aims to determine if the higher dose given less frequently is as effective as the lower dose given more frequently. Participants will receive injections over a period of time, and their vision will be monitored to see how it changes with the treatment.

Throughout the study, participants will have their vision tested using a method called the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, which measures how well they can see letters on a chart. The study will also track the number of injections participants receive and any side effects they may experience. The goal is to find the best treatment option for improving vision in people with macular edema due to retinal vein occlusion.

]]>